To support the developpement of new therapies based on nucleic acid delivery, Polyplus-transfection® offers reagents manufactured in complience with European Commision and FDA guidelines. The reagents are supported by the appropriate manufacturing quality controls, documentation and certification required for preclinical and clinical trials from phase I to III.

In addition, Polyplus-transfection® offers novel classes of modified oligonucleotides available for licensing for a wide range of applications including therapeutic purposes.